Cite
HARVARD Citation
Yalcin, A. et al. (n.d.). Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1β and sCD200 in cases of Samter's syndrome: 36 months follow-up. Immunopharmacology and immunotoxicology. pp. 524-527. [Online].